SEARCH

SEARCH BY CITATION

References

  • 1
    Dahlback B, Carlsson M, Svensoon PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993; 90: 10041008.
  • 2
    Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 6467.
  • 3
    Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemostas 1995; 74: 94100.
  • 4
    Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation 1994; 344; 14531457.
  • 5
    Dahlback B. Physiologic anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 25212524.
  • 6
    Rai R, Regan L, Hadley E, Dave M, Cohen H. Second trimester pregnancy loss is associated with activated protein C resistance. Thromb Haemostas 1995; 73: 1300.
  • 7
    Younis JS, Ben-Ami M, Brenner B, Lanir N, Rothbart H, Ohel G. The association of repeat fetal demise with activated protein C resistance and factor V Leiden. Gynecol Endocrinol 1996; 10: 164.
  • 8
    Younis JS, Ohel G, Brenner B, Ben-Ami M. Familial thrombophilia—the scientific rationale for thrombophylaxis in recurrent pregnancy loss Hum Reprod 1997; 12: 13891390.
  • 9
    Brenner B, Mandel H, Lanir N et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97: 551554.
  • 10
    Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996; 92: 489490.
  • 11
    Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913916.
  • 12
    Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemostas 1997; 77: 822824.
  • 13
    Ridker PM, Miletich JP, Buring JE et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128: 10001003.
  • 14
    Balash J, Reverter JC, Fabregues F et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod 1997; 12: 10941097.
  • 15
    Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34: 217223.
  • 16
    Silver RM, Branch DW. Recurrent miscarriage: autoimmune considerations. Clin Obstet Gynecol 1994; 37: 745760.
  • 17
    Brenner B, Blumenfeld Z. Thrombophilia and fetal loss. Blood Reviews 1997; 11: 7279.
  • 18
    Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 15841589.
  • 19
    Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253257.
  • 20
    Seligsohn U, Zivelin A. Thrombophilia as multigenic disorder. Thromb Haemostas 1997; 78: 297301.
  • 21
    Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993; 78: 313318.